
Biogen Inc. owns 6 brands in our database. Browse the complete portfolio of Biogen Inc. subsidiaries and brands across various industries.
Company Type
public
Headquarters
Cambridge, Massachusetts, USA
Brand Portfolio
6 brands
Stock
NASDAQ: BIIB
Healthcare PharmaceuticalsOwned by Biogen Inc.
The biotechnology brand of Biogen Inc., focused on neurology therapeutics.
Healthcare PharmaceuticalsOwned by Biogen Inc.
The Alzheimer's disease antibody therapy co-commercialized by Biogen and Eisai.
Healthcare PharmaceuticalsOwned by Biogen Inc.
The Friedreich's ataxia therapy brand of Biogen, acquired through the 2023 Reata deal.
Healthcare PharmaceuticalsOwned by Biogen Inc.
The spinal muscular atrophy antisense therapy brand of Biogen.
Healthcare PharmaceuticalsOwned by Biogen Inc.
The multiple sclerosis infusion therapy brand of Biogen, marketed for two decades.
Healthcare PharmaceuticalsOwned by Biogen Inc.
The postpartum depression therapy brand of Biogen and Sage Therapeutics.
Is Biogen publicly traded?
Yes. It trades on NASDAQ under ticker BIIB.
What is Biogen's biggest drug?
Spinraza and Tysabri remain leading revenue products as the MS franchise declines; growth is led by Skyclarys, Zurzuvae, and Leqembi.
Who is the CEO of Biogen?
Christopher Viehbacher, president and chief executive officer.
Does Biogen make Leqembi?
Yes. Biogen co-develops and co-markets Leqembi (lecanemab) with Eisai.
No competing brands found in the same categories. This could be because Biogen Inc.operates in unique market segments or we're still building our competitor database.
Biogen Inc. maintains a diverse portfolio of 6 brands across multiple industries. This comprehensive brand portfolio demonstrates the company's market presence and strategic business units.
For consumers and researchers interested in corporate ownership structures, understanding which brands are owned by Biogen Inc.provides valuable insights into market dynamics, product relationships, and corporate strategy.